pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2017-27-5-672-678pulmo-925Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯCLINICAL PHARMACOLOGYСолфордское исследование – путь к улучшению контроля над бронхиальной астмой в реальной клинической практике (обзор клинического исследования)The Salford Lung Study is a way to improve asthma control in real clinical practice (a review)ВаргинаВ. Н.VarginaV. N.

 

к. м. н., медицинский менеджер респираторного направления

тел.: 495-777-89-00

121614, Москва, ул. Крылатская, 17, корп. 3

Candidate of Medicine, Medical Affairs Manager, Respiratory Portfolio

 tel.: 495-777-89-00

ul. Krylatskaya 17, build. 3, Moscow, 121614, Russia

victoria.n.vargina@gsk.comБарабановаЕ. Н.BarabanovaE. N.

 

к. м. н., менеджер по научно-медицинским коммуникациям

 

тел. 495-777-89-00

121614, Москва, ул. Крылатская, 17, корп. 3

 

Candidate of Medicine, Medical & Scientific Communications Manager

 

tel.: 495-777-89-00

ul. Krylatskaya 17, build. 3, Moscow, 121614, Russia

ekaterina.n.barabanova@gsk.comЗАО «ГлаксоСмитКляйн Трейдинг»РоссияCJC GlaxoSmithKline TraidingRussian Federation201724122017275672678Copyright © Варгина В.Н., Барабанова Е.Н., 20172017Варгина В.Н., Барабанова Е.Н.Vargina V.N., Barabanova E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/925

Солфордское исследование легких у пациентов с бронхиальной астмой (БА) (Salford Lung Study – Asthma, SLS-Астма) является первым проспективным рандомизированным контролируемым клиническим исследованием, которое проводилось в условиях и в популяции, максимально соответствующих реальной клинической практике. Выявлено, что в крупной разнородной популяции больных БА при лечении комбинацией вилантерола и флутиказона фуроата (ВИ / ФФ) 22 / 92 или 22 / 184 мкг 1 раз в день в порошковом ингаляторе Эллипта обеспечивался лучший контроль над заболеванием, чем в случае стандартной терапии, назначаемой и изменяемой по усмотрению врача. Уровень контроля над БА в группе ВИ / ФФ стабильно поддерживался на протяжении 12 мес., при этом изменения риска развития серьезных нежелательных явлений не выявлено. Получены сходные результаты у пациентов, получавших ингаляционные глюкокортикостероиды и их комбинацию с длительно действующими β2-агонистами, не зависящие от статуса курения и количества обострений за прошедший год.

The Salford Lung Study in asthma (SLS-Asthma) is the first prospective, randomized, controlled clinical trial conducted in conditions and in population that were very close to real clinical practice. The study demonstrated that treatment of a large heterogeneous population of asthma patients using combination of vilanterol (VI) and fluticasone furoate (FF) (22/92 mg q.d. or 22/184 mg q.d.) via Ellipta dry powder inhaler provided better control of the disease than the conventional therapy administered by an attendant physician. The level of asthma control in VI/FF group was consistently maintained for 12 months with no identified change in risk of development of serious adverse events. Results were similar in patients receiving ICS or ICS/LABA combinations and did not depend on smoking status or number of exacerbations over the previous year.

бронхиальная астмаингаляционные глюкокортикостероидыдлительно действующие #b2-агонистывилантеролфлутиказона фуроатЭллиптаbronchial asthmainhaled corticosteroidslong-acting β-agonistsvilanterolfluticasone furoateElliptaReferencesGlobal Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2017. Available at: www.ginasthma.com [Accessed 03 October, 2017].Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2017. Available at: www.ginasthma.com [Accessed 03 October, 2017].Hannan E.L. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc. Interv. 2008; 1 (3): 211–217. DOI: 10.1016/j.jcin.2008.01.008.Hannan E.L. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc. Interv. 2008; 1 (3): 211–217. DOI: 10.1016/j.jcin.2008.01.008.Herland K., Akselsen J.P., Skjønsberg O.H., Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir. Med. 2005; 99 (1): 11–19. DOI: 10.1016/j.rmed.2004.03.026.Herland K., Akselsen J.P., Skjønsberg O.H., Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir. Med. 2005; 99 (1): 11–19. DOI: 10.1016/j.rmed.2004.03.026.Agusti A.A., de Teresa L., De Backer W. et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. J. Eur. Respir. 2014; 43 (3): 763–772. DOI: 10.1183/09031936.00054213.Agusti A.A., de Teresa L., De Backer W. et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. J. Eur. Respir. 2014; 43 (3): 763–772. DOI: 10.1183/09031936.00054213.Tamura G., Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir. Med. 2007; 101 (9): 1895–1902. DOI: 10.1016/j.rmed.2007.05.001.Tamura G., Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir. Med. 2007; 101 (9): 1895–1902. DOI: 10.1016/j.rmed.2007.05.001.Berger M.L., Dreyer N., Anderson F. et al. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health. 2012; 15 (2): 217–230. DOI: 10.1016/j.jval.2011.12.010.Berger M.L., Dreyer N., Anderson F. et al. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health. 2012; 15 (2): 217–230. DOI: 10.1016/j.jval.2011.12.010.Woodcock A., Vestbo J., Bakerly N.D. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017; Published online September 10, 2017. DOI: 10.1016/S0140-6736(17)32397-8.Woodcock A., Vestbo J., Bakerly N.D. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017; Published online September 10, 2017. DOI: 10.1016/S0140-6736(17)32397-8.Thomas M., Kay S., Pike J. et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim. Care Respir. J. 2009; 18 (1): 41–49. DOI: 10.4104/pcrj.2009.00010.Thomas M., Kay S., Pike J. et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim. Care Respir. J. 2009; 18 (1): 41–49. DOI: 10.4104/pcrj.2009.00010.Schatz M., Sorkness C.A., Li J.T. et al. Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J. Allergy Clin. Immunol. 2006; 117 (3): 549–556.Schatz M., Sorkness C.A., Li J.T. et al. Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J. Allergy Clin. Immunol. 2006; 117 (3): 549–556.Ko F.W., Hui D.S., Leung T.F. et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology. 2012; 17: 370–378. DOI: 10.1111/j.1440-1843.2011.02105.x.Ko F.W., Hui D.S., Leung T.F. et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology. 2012; 17: 370–378. DOI: 10.1111/j.1440-1843.2011.02105.x.Soler X., Holbrook J.T., Gerald L.B. et al. Validity of the Asthma Control Test Questionnaire among Smoking Asthmatics. J. Allergy Clin. Immunol. Pract. 2017 [Epub. ahead of print].Soler X., Holbrook J.T., Gerald L.B. et al. Validity of the Asthma Control Test Questionnaire among Smoking Asthmatics. J. Allergy Clin. Immunol. Pract. 2017 [Epub. ahead of print].de Araujo G.V., Leite D.F., Rizzo J.A., Sarinho E.S. Asthma in pregnancy: association between the Asthma Control Test and the Global Initiative for Asthma classification and comparisons with spirometry. Eur. J. Obstet. Gynecol. Reprod. Biol. 2016; 203: 25–29.de Araujo G.V., Leite D.F., Rizzo J.A., Sarinho E.S. Asthma in pregnancy: association between the Asthma Control Test and the Global Initiative for Asthma classification and comparisons with spirometry. Eur. J. Obstet. Gynecol. Reprod. Biol. 2016; 203: 25–29.Schatz M., Mosen D.M., Kosinki M. et al. Validity of the Asthma Control Test completed at home. Am. J. Manag. Carе. 2007; 13 (12): 661–667.Schatz M., Mosen D.M., Kosinki M. et al. Validity of the Asthma Control Test completed at home. Am. J. Manag. Carе. 2007; 13 (12): 661–667.Peters S.P., Jones C.A., Haselkorn T. et al. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national web-based survey. J. Allergy Clin. Immunol. 2007; 119: 1454–1461.Peters S.P., Jones C.A., Haselkorn T. et al. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national web-based survey. J. Allergy Clin. Immunol. 2007; 119: 1454–1461.Schatz M., Mosen D.M. Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology. J. Allergy Clin. Immunol. 2007; 119: 336–343.Schatz M., Mosen D.M. Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology. J. Allergy Clin. Immunol. 2007; 119: 336–343.Gibson P. Effectiveness trials in asthma: time to SaLSA? Lancet. 2017. Published online September 10, 2017.Gibson P. Effectiveness trials in asthma: time to SaLSA? Lancet. 2017. Published online September 10, 2017.

The authors declare that there are no conflicts of interest present.